Efficacy and quality‐of‐life improvements with fremanezumab treatment in patients with difficult‐to‐treat migraine with associated neurological dysfunction-Reference-Cited by-同舟云学术

Efficacy and quality‐of‐life improvements with fremanezumab treatment in patients with difficult‐to‐treat migraine with associated neurological dysfunction

Published:2022-03-29 Issue:7 Volume:29 Page:2129-2137
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Lampl Christian¹^ORCID,Rapoport Alan M.²,Cohen Joshua M.³,Barash Steve⁴,Ramirez Campos Verena³,Seminerio Michael J.⁵,Ning Xiaoping⁶,Silberstein Stephen D.⁷

Affiliation:

1. Department of Neurology and Headache Medical Centre Konventhospital Barmherzige Brüder Linz Linz Austria

2. Department of Neurology David Geffen School of Medicine at UCLA Los Angeles California USA

3. Global Medical Affairs Teva Branded Pharmaceutical Products R&D, Inc. West Chester Pennsylvania USA

4. Statistics Teva Branded Pharmaceutical Products R&D, Inc. West Chester Pennsylvania USA

5. North American Medical Affairs Teva Pharmaceuticals USA, Inc. Parsippany New Jersey USA

6. Global Clinical Development Teva Branded Pharmaceutical Products R&D, Inc. West Chester Pennsylvania USA

7. Jefferson Headache Center Thomas Jefferson University Philadelphia Pennsylvania USA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.15328

Reference22 articles.

1. One-Year Prevalence of Migraine in Austria: A Nation-Wide Survey

2. Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe Headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study

3. The International Classification of Headache Disorders, 3rd edition (beta version)

4. The typical duration of migraine aura: A systematic review

5. Variability of clinical features in attacks of migraine with aura